Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Advances in Therapy
Published in: Advances in Therapy 1/2020

Open Access 01-01-2020 | Metastasis | Review

Paraneoplastic Syndromes Associated with Laryngeal Cancer

Authors: Alessandra Rinaldo, Andrés Coca-Pelaz, Carl E. Silver, Alfio Ferlito

Published in: Advances in Therapy | Issue 1/2020

Login to get access

Abstract

Objectives

Paraneoplastic syndromes occur rarely in association with laryngeal cancer. When present, the syndrome may be the first sign of the malignancy. The aim of the present study was to review and report on all published cases in the international literature.

Methods

A search of PubMed was conducted for “paraneoplastic syndromes in laryngeal cancer” without any restrictions on language or publication year. The full texts of all relevant articles were reviewed and all cases of paraneoplastic syndromes associated with any type of laryngeal cancer were extracted and analyzed.

Results

We identified 59 cases of paraneoplastic syndromes related to laryngeal cancer in the literature published from 1963 until recently. There were 46 squamous cell carcinomas and 10 neuroendocrine carcinomas. Twenty-two of the paraneoplastic syndromes involved the endocrine system, 21 were dermatologic or cutaneous, 8 neurologic, 5 osteoarticular or rheumatologic, 1 ocular, 1 muscular, and 1 hematologic. Treatment strategies included surgery, radiotherapy, chemotherapy, and often multimodal therapy, depending on the histology and stage of the laryngeal cancer.

Conclusions

Because of their rarity, paraneoplastic syndromes associated with laryngeal cancer are difficult to diagnose. By presenting and systematically reviewing all published cases in the international literature, the present review may help clinicians to recognize them and to suspect the diagnosis of laryngeal cancer at an earlier stage than otherwise might be possible.
Literature
1.
Ferlito A, Rinaldo A. Paraneoplastic syndromes in patients with laryngeal and hypopharyngeal cancers. Ann Otol Rhinol Laryngol. 2000;109:109–17.PubMedCrossRef
2.
Ferlito A, Rinaldo A. Paraneoplastic syndromes in patients with cancer of the larynx and hypopharynx. Ann Otol Rhinol Laryngol. 2007;116:502–13.PubMedCrossRef
3.
4.
Henry K. Paraneoplastic syndromes: definitions, classification, pathophysiology and principles of treatment. Semin Diagn Pathol. 2019;36:204–10.PubMedCrossRef
5.
Ferlito A, Friedmann I. Neuroendocrine neoplasms. In: Ferlito A, editor. Neoplasms of the larynx. Edinburgh: Churchill Livingstone; 1993. p. 169–205.
6.
Mason WP, Graus F, Lang B, et al. Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert–Eaton myasthenic syndrome. Brain. 1997;120:1279–300.PubMedCrossRef
7.
8.
Sillevis Smitt P, Grefkens J, de Leeuw B, et al. Survival and outcome in 73 anti-Hu positive patients with paraneoplastic encephalomyelitis/sensory neuronopathy. J Neurol. 2002;249:745–53.PubMedCrossRef
9.
10.
Gandhi L, Johnson BE. Paraneoplastic syndromes associated with small cell lung cancer. J Natl Compr Canc Netw. 2006;4:631–8.PubMedCrossRef
11.
Ferlito A, Rinaldo A, Devaney KO. Syndrome of inappropriate antidiuretic hormone secretion associated with head and neck cancers: review of the literature. Ann Otol Rhinol Laryngol. 1997;106:878–83.PubMedCrossRef
12.
Ferlito A, Shaha AR, Rinaldo A. Paraneoplastic syndromes in neuroendocrine neoplasms of the head and neck: have they an impact on prognosis? (Editorial). Acta Otolaryngol. 2001;121:756–8.PubMedCrossRef
13.
Ferlito A, Rinaldo A, Bishop JA, et al. Paraneoplastic syndromes in patients with laryngeal neuroendocrine carcinomas: clinical manifestations and prognostic significance. Eur Arch Otorhinolaryngol. 2016;273:533–6.PubMedCrossRef
14.
Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;350:g7647.PubMedCrossRef
15.
Kurzrock R, Cohen PR. Cutaneous paraneoplastic syndromes in solid tumors. Am J Med. 1995;99:662–71.PubMedCrossRef
16.
Oppolzer G, Schwarz T, Zechner G, Gschnait F. [Acanthosis nigrigans in squamous cell carcinoma of the larynx]. Z Hautkr. 1986;61:1229–37. (Article in German).PubMed
17.
Khachemoune A, Yalamanchili R, Rodriguez C. Bazex syndrome (paraneoplastic acrokeratosis). Cutis. 2004;74:289–92.PubMed
18.
Valdivielso M, Longo I, Suarez R, Huerta M, Lazaro P. Acrokeratosis paraneoplastica: Bazex syndrome. J Eur Acad Dermatol Venereol. 2005;19:340–4.PubMedCrossRef
19.
Laccourreye O, Laccourreye L, Jouffre V, Brasnu D. Bazex’s acrokeratosis paraneoplastica. Ann Otol Rhinol Laryngol. 1996;105:487–9.PubMedCrossRef
20.
Bazex A, Salvador R, Dupré A, Christol B. Syndrome paranéoplasique à type d’hyperkératose des extrémités. Guérison après le traitement de l’épithélioma laryngé. Bull Soc Fr Dermatol Syphil. 1965;72:182.
21.
Bazex J, El Sayed F, Sans B, Marguery MC, Samalens G. Acrokératose paranéoplasique de Bazex associée a une ichtyose acquise, des troubles de la pigmentation et un prurit: révélation tardive d’un néoplasme laryngé. Ann Dermatol Venereol. 1992;119:483–5.PubMed
22.
Blanchet F, Leroy D, Deschamps P. Acrokératose paranéoplasique de Bazex. A propos de 8 cas. J Fr Otorhinolaryngol. 1980;29:165–72.PubMed
23.
Colomb D, Reboul MC, Mauduit G, Forestier JY. Forme diffuse d’acrokératose paranéoplasique de Bazex révélatrice d’une récidive et de métastases d’un cancer de l’épiglotte antérieurement traité. Ann Dermatol Venereol. 1981;108:885–8.PubMed
24.
Gaillard J, Haguenauer JP, Dubreuil C, Romanet P. Acrokératose de Bazex, syndrome paranéoplasique révélateur d’une métastase d’un cancer de la vallécule guéri localement à trois ans. J Fr Otorhinolaryngol. 1978;27:353–7.PubMed
25.
Legros M, Kalis B, Brunetaud P, Longuebray A. Cancer pharyngo-laryngé et acrokératose de Bazex. Ann Otolaryngol Chir Cervicofac. 1977;94:47–52.PubMed
26.
Miquel FJ, Zapater E, Vilata JJ, Gil MP, Garin L. Paraneoplastic acral hyperkeratosis: initial sign of laryngeal neoplasia. Otolaryngol Head Neck Surg. 1997;117:S239–42.PubMedCrossRef
27.
28.
Plasencia DP, Lazarich JMC, Macias AR. Acrokeratosisparaneoplastica (Bazex syndrome) with ear manifestation. Mediterranean J Otol. 2005;1:148–51.
29.
Sarkar B, Knecht R, Sarkar C, Weidauer H. Bazex syndrome (acrokeratosisparaneoplastica). Eur Arch Otorhinolaryngol. 1998;255:205–10.PubMedCrossRef
30.
Aksu G, Karadeniz A. Cutaneous paraneoplastic syndrome (acrokeratosisparaneoplastica) preceding squamous cell carcinoma of the glottic larynx. N Z Med J. 2006;119:U2006.PubMed
31.
Milewski C, Wieland W. Paraneoplastische Akrokeratose: M. Bazex Eine tumorspezifische Dermatose bei Plattenepithelkarzinomen im Kopf-Halsbereich. HNO. 1988;36:158–60.PubMed
32.
Wareing MJ, Vaughan-Jones SA, McGibbon DH. Acrokeratosisparaneoplastica: Bazex syndrome. J Laryngol Otol. 1996;110:899–900.PubMedCrossRef
33.
Hodge L, Marsden RA, Black MM, Bhogal B, Corbett MF. Bullous pemphigoid: the frequency of mucosal involvement and concurrent malignancy related to indirect immunofluorescence findings. Br J Dermatol. 1981;105:65–9.PubMedCrossRef
34.
Balestri R, Magnano M, La Placa M, et al. Malignancies in bullous pemphigoid: a controversial association. J Dermatol. 2016;43:125–33.PubMedCrossRef
35.
Bonnetblanc JM, Bernard P, Fayol J. Dermatomyositis and malignancy: a multicenter cooperative study. Dermatologica. 1990;180:212–6.PubMedCrossRef
36.
Mackenzie AH, Scherbel AL. Connective tissue syndromes associated with carcinoma. Geriatrics. 1963;18:745–53.PubMed
37.
Guin JD, Elleman JH. Yellow nail syndrome. Possible association with malignancy. Arch Dermatol. 1979;115:734–5.PubMedCrossRef
38.
39.
Batinac T, Kujundzić M, Peternel S, Cabrijan L, Troselj-Vukić B, Petranović D. Pityriasis rubra pilaris in association with laryngeal carcinoma. Clin Exp Dermatol. 2009;34:e917–9.PubMedCrossRef
40.
Nyati A, Kalwaniya S, Jain S, Soni B. Sign of Leser-Trélat in association with laryngeal carcinoma. Indian J Dermatol Venereol Leprol. 2016;82:112.PubMedCrossRef
41.
Soga J. Carcinoids and their variant endocrinomas. An analysis of 11842 reported cases. J Exp Clin Cancer Res. 2003;22:517–30.PubMed
42.
Soga J. Early-stage carcinoids of the gastrointestinal tract: an analysis of 1914 reported cases. Cancer. 2005;103:1587–895.PubMedCrossRef
43.
Soga J, Yakuwa Y, Osaka M. Carcinoid syndrome: a statistical evaluation of 748 reported cases. J Exp Clin Cancer Res. 1999;18:133–41.PubMed
44.
Ferlito A, Rinaldo A. The spectrum of endocrinocarcinomas of the larynx. Oral Oncol. 2005;41:878–83.PubMedCrossRef
45.
Ferlito A, Devaney KO, Rinaldo A. Neuroendocrine neoplasms of the larynx: advances in identification, understanding and management. Oral Oncol. 2006;42:770–88.PubMedCrossRef
46.
Baugh RF, Wolf GT, Lloyd RV, McClatchey KD, Evans DA. Carcinoid (neuroendocrine carcinoma) of the larynx. Ann Otol Rhinol Laryngol. 1987;96:315–21.PubMedCrossRef
47.
Kumai M, Arakawa T, Nakane T, et al. Serum serotonin elevated carcinoid tumor of the larynx (in Japanese). Larynx Jpn. 1996;8:53–5.CrossRef
48.
Overholt SM, Donovan DT, Schwartz MR, Laucirica R, Green LK, Alford BR. Neuroendocrine neoplasms of the larynx. Laryngoscope. 1995;105:789–94.PubMedCrossRef
49.
Wenig BM, Gnepp DR. The spectrum of neuroendocrine carcinomas of the larynx. Semin Diagn Pathol. 1989;6:329–50.PubMed
50.
Yamanaka J, Yao K, Kohno H. A case of primary laryngeal carcinoid with the carcinoid syndrome and rapid clinical course (in Japanese). Kitasato Med. 1997;27:110–3.
51.
Imura H, Matsukura S, Yamamoto H, Hirata Y, Nakai Y. Studies on ectopic ACTH-producing tumors. II. Clinical and biochemical features of 30 cases. Cancer. 1975;35:1430–7.PubMedCrossRef
52.
Bishop JW, Osamura RY, Tsutsumi Y. Multiple hormone production in an oat cell carcinoma of the larynx. Acta Pathol Jpn. 1985;35:915–23.PubMed
53.
Schwartz WB, Warren B, Curelop S, Bartter FC. A syndrome of renal sodium loss and hyponatremia probably resulting from inappropriate secretion of antidiuretic hormone. Am J Med. 1957;23:529–42.PubMedCrossRef
54.
Kandylis KV, Vasilomanolakis M, Efremides AD. Syndrome of inappropriate antidiuretic hormone secretion in pyriform sinus squamous cell carcinoma. Am J Med. 1986;81:946.PubMedCrossRef
55.
Moses AM, Miller M, Streeten DHP. Pathophysiologic and pharmacologic alterations in the release and action of ADH. Metabolism. 1976;25:697–721.PubMedCrossRef
56.
Roth Y, Lightman SL, Kronenberg J. Hyponatremia associated with laryngeal squamous cell carcinoma. Eur Arch Otorhinolaryngol. 1994;251:183–5.PubMedCrossRef
57.
Talmi YP, Hoffman HT, McCabe BF. Syndrome of inappropriate secretion of arginine vasopressin in patients with cancer of the head and neck. Ann Otol Rhinol Laryngol. 1992;101:946–9.PubMedCrossRef
58.
Zohar Y, Talmi YP, Finkelstein Y, Nobel M, Gafter U. The syndrome of inappropriate antidiuretic hormone secretion in cancer of the head and neck. Ann Otol Rhinol Laryngol. 1991;100:341–4.PubMedCrossRef
59.
Trotoux J, Glickmanas M, Sterkers O, Trousset M, Pinel J. Syndrome de Schwartz-Bartter: révélateur d’un cancer laryngé sousglottique à petites cellules. Ann Otolaryngol Chir Cervicofac. 1979;96:349–58.PubMed
60.
Takeuchi K, Nishii S, Jin CS, Ukai K, Sakakura Y. Anaplastic small cell carcinoma of the larynx. Auris Nasus Larynx. 1989;16:127–32.PubMedCrossRef
61.
Myers TJ, Kessimian N. Small cell carcinoma of the larynx and ectopic antidiuretic hormone secretion. Otolaryngol Head Neck Surg. 1995;113:301–4.PubMedCrossRef
62.
Mundy GR. Ectopic production of calciotropic peptides. Endocrinol Metab Clin N Am. 1991;20:473–87.CrossRef
63.
Mundy GR, Ibbotson KJ, D’Souza SM, Simpson EL, Jacobs JW, Martin TJ. The hypercalcemia of cancer: clinical implications and pathogenic mechanisms. N Engl J Med. 1984;310:1718–27.PubMedCrossRef
64.
Plimpton CH, Gellhorn A. Hypercalcemia in malignant disease without evidence of bone destruction. Am J Med. 1956;21:750–9.PubMedCrossRef
65.
Angel MF, Stewart A, Pensak ML, Pillsbury HRC, Sasaki CT. Mechanisms of hypercalcemia in patients with head and neck cancer. Head Neck Surg. 1982;5:125–9.PubMedCrossRef
66.
Zhang R, Li J, Assaker G, et al. Parathyroid hormone-related protein (PTHrP): an emerging target in cancer progression and metastasis. Adv Exp Med Biol. 2019;1164:161–78.PubMedCrossRef
67.
Minotti AM, Kountakis SE, Stiernberg CM. Paraneoplastic syndromes in patients with head and neck cancer. Am J Otolaryngol. 1994;15:336–43.PubMedCrossRef
68.
Trousseau A. Phlegmasia alba dolens. Clinique Medicale de l’Hôtel-Dieu de Paris, vol. 3. London: New Sydenham Society; 1865.
69.
Evans TRJ, Mansi JL, Bevan DH. Trousseau’s syndrome in association with ovarian carcinoma. Cancer. 1996;77:2544–9.PubMedCrossRef
70.
Sack GH Jr, Levin J, Bell WR. Trousseau’s syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features. Medicine (Baltimore). 1977;56:1–37.CrossRef
71.
Nikšic M, Balogh M. Über Gerinnungsstörungen bei Kehlkopf- und Rachen-Malignomen. Laryngorhinootologie. 1976;55:414–9.
72.
Naschitz JE, Yeshurun D, Eldar S, Lev LM. Diagnosis of cancer-associated vascular disorders. Cancer. 1996;77:1759–67.PubMedCrossRef
73.
Liu PG, Jacobs JB, Reede D. Trousseau’s syndrome in the head and neck. Am J Otolaryngol. 1985;6:405–8.PubMedCrossRef
74.
Garcin R, Lapresle J. Sur un cas d’atrophie cérébelleuse corticale subaigue en relation avec un épithélioma du larynx. Arch Pathol. 1956;62:399–402.
75.
Müller E, Spanke O, Lehmann I. Neurogene Störungen bei extrazerebralen Malignomen. Med Klin. 1969;64:1470–5.PubMed
76.
77.
Cher LM, Hochberg FH, Teruya J, et al. Therapy for paraneoplastic neurologic syndromes in six patients with protein A column immunoadsorption. Cancer. 1995;75:1678–83.PubMedCrossRef
78.
Garcia FJ, Blazquez JA, Perez-Moro E, Martinez S. [Paraneoplastic ataxia due to laryngeal carcinoma]. Acta Otorrinolaringol Esp. 1998;49:414–5. (Article in Spanish).PubMed
79.
Lambert E, Eaton L, Rooke E. Defect of neuromuscular conduction associated with malignant neoplasm. Am J Physiol. 1956;187:612.
80.
Eaton LM, Lambert EH. Electromyography and electric stimulation of nerves in diseases of motor unit: observation on the myasthenic syndrome associated with malignant tumors. JAMA. 1957;183:183–99.
81.
82.
Seute T, Leffers P, ten Velde GP, Twijnstra A. Neurologic disorders in 432 consecutive patients with small cell lung carcinoma. Cancer. 2004;100:801–6.PubMedCrossRef
83.
Fontanel J-P, Betheuil MJ, Sénéchal G, Haguenau M. Un cas de syndrome de Lambert-Eaton secondaire à un épithélioma laryngé. Ann Otolaryngol Chir Cervicofac. 1973;90:314–7.PubMed
84.
Medina JE, Moran M, Goepfert H. Oat cell carcinoma of the larynx and Eaton–Lambert syndrome. Arch Otolaryngol. 1984;110:123–6.PubMedCrossRef
85.
Ferroir JP, Hervier-Caen C, Reignier A, Nicolle MH, Guillard A. [Remission of Lambert–Eaton syndrome over a 10-year period. Recurrence without evidence of tumor at autopsy]. Rev Neurol (Paris). 1989;145:851–2. (Article in French).
86.
Shipley E, Krim E, Deminière C, Lagueny A. [Lambert–Eaton myasthenic syndrome associated with vocal cord carcinoma]. Rev Neurol (Paris). 2008;164:72–6. (Article in French).CrossRef
87.
Wymenga AN, Slebos DJ, van der Naalt J, van Putten JW, Peters FT. [Abdominal complaints and neurological symptoms as an early sign of lung cancer: a manifestation of the anti-Hu syndrome]. Ned Tijdschr Geneeskd. 2003;147:616–9. (Article in Dutch).PubMed
88.
Baijens LW, Manni JJ. Paraneoplastic syndromes in patients with primary malignancies of the head and neck. Four cases and a review of the literature. Eur Arch Otorhinolaryngol. 2006;263:32–6.PubMedCrossRef
89.
Erro Aguirre ME, Gila L, Olaziregui O. [Paraneoplastic sensory neuropathy associated with squamous cell carcinoma of the larynx]. Neurologia. 2016;31:286–8. (Article in Spanish).PubMedCrossRef
90.
Stummvoll GH, Aringer M, Machold KP, Smolen JS, Raderer M. Cancer polyarthritis resembling rheumatoid arthritis as a first sign of hidden neoplasms. Report of two cases and review of the literature. Scand J Rheumatol. 2001;30:40–4.PubMedCrossRef
91.
Eggelmeijer F, Macfarlane JD. Polyarthritis as the presenting symptom of the occurrence and recurrence of a laryngeal carcinoma. Ann Rheum Dis. 1992;51:556–7.PubMedPubMedCentralCrossRef
92.
Cabane J, Lebas J, Wattiaux MJ, Imbert JC. [Pseudo-Still disease and neoplasm. 2 cases]. Rev Med Interne. 1988;9:81–4. (Article in French).PubMedCrossRef
93.
Cohen PR. Hypertrophic pulmonary osteoarthropathy and tripe palms in a man with squamous cell carcinoma of the larynx and lung. Report of a case and review of cutaneous paraneoplastic syndromes associated with laryngeal and lung malignancies. Am J Clin Oncol. 1993;16:268–76.PubMedCrossRef
94.
Bataller L, Dalmau J. Neuro-ophthalmology and paraneoplastic syndromes. Curr Opin Neurol. 2004;17:3–8.PubMedCrossRef
95.
Parc CE, Azan E, Bonnel S, Sahel JA, Kaplan J, Thirkill CE. Cone dysfunction as a paraneoplastic syndrome associated with retinal antigens approximating 40 kiloDalton. Ophthalmic Genet. 2006;27:57–61.PubMedCrossRef
96.
Hill CL, Zhang Y, Sigurgeirsson B, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet. 2001;357:96–100.PubMedCrossRef
97.
Sahu R, Rathaur BP, Chaudhari TS, Shukla R, Malhotra KP. Laryngeal carcinoma presenting as polymyositis: a paraneoplastic syndrome. Ann Indian Acad Neurol. 2016;19:150–1.PubMedPubMedCentralCrossRef
98.
Rubisz-Brzezinska J, Zebracka T, Musialowicz D. Coexistence of 2 paraneoplastic syndromes—acrokeratosis Bazex and Leser-Trèlat syndrome—in a case of squamous-cell laryngeal cancer. Przegl Dermatol. 1983;70:205–8.PubMed
99.
Ehmann LM, Grahovac M, Kramer M, Ruzicka T, Wollenberg A. Paraneoplastic palmoplantar hyperkeratosis. Minor form of acrokeratosis neoplastica Bazex? Hautarzt. 2012;63:477–9.PubMedCrossRef
100.
Tsvetkov EA. [Dermatomyositis as a complication of the radiotherapy of laryngeal cancer]. Med Radiol (Mosk). 1977;22:78–9. (Article in Russian).
101.
Zhang W, Jiang SP, Huang L. Dermatomyositis and malignancy: a retrospective study of 115 cases. Eur Rev Med Pharmacol Sci. 2009;13:77–80.PubMed
102.
Maxwell EL, Witterick IJ. Syndrome of inappropriate antidiuretic hormone in a patient with metastatic supraglottic cancer. J Otolaryngol. 2004;33:308–9.PubMedCrossRef
Metadata
Title
Paraneoplastic Syndromes Associated with Laryngeal Cancer
Authors
Alessandra Rinaldo
Andrés Coca-Pelaz
Carl E. Silver
Alfio Ferlito
Publication date
01-01-2020
Publisher
Springer Healthcare
Published in
Advances in Therapy / Issue 1/2020
Print ISSN: 0741-238X
Electronic ISSN: 1865-8652
DOI
https://doi.org/10.1007/s12325-019-01160-9

Other articles of this Issue 1/2020

Advances in Therapy 1/2020 Go to the issue

Original Research

Cost-Effectiveness of Reimbursing Infliximab for Moderate to Severe Crohn’s Disease in China

Original Research

Epidural Corticosteroids, Lumbar Spinal Drainage, and Selective Hemodynamic Control for the Prevention of Spinal Cord Ischemia in Thoracoabdominal Endovascular Aortic Repair: A New Clinical Protocol

Original Research

Long-Term Safety of Adalimumab in 29,967 Adult Patients From Global Clinical Trials Across Multiple Indications: An Updated Analysis

Original Research

Cancer-Specific Loss of Urocortin 3 in Human Renal Cancer

Original Research

Cost-Effectiveness of Treating Early to Moderate Stage Knee Osteoarthritis with Intra-articular Hyaluronic Acid Compared to Conservative Interventions

Original Research

Topical Low Dose Preservative-Free Hydrocortisone Reduces Signs and Symptoms in Patients with Chronic Dry Eye: A Randomized Clinical Trial

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits